arginyl-glycyl-aspartic acid peptide

Arginyl-glycyl-aspartic acid peptide (RGD peptide) is a synthetic, designer integrin-blocking peptide developed by researchers at the Nencki Institute of Experimental Biology. It is designed to disrupt the immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) by targeting the interactions between tumor cells and glioma-associated myeloid cells (GAMs). By blocking integrin-mediated signaling, the peptide prevents the reprogramming of myeloid cells into protumoral GAMs and promotes the normalization of peritumoral blood vessels. In preclinical studies, intratumoral delivery of this RGD peptide has demonstrated the ability to convert a "cold" immunosuppressive TME into a "hot" inflammatory one, significantly enhancing the efficacy of immune checkpoint inhibitors such as anti-PD-1 antibodies by increasing effector T-cell infiltration and depleting regulatory T cells.

Other names

Arg-Gly-Asparginyl-glycyl-aspartic aciddesigner RGD peptide